Hormone & Peptide Therapy Disclaimer

Last updated: July 2, 2025

General Medical Disclaimer
Hormone therapy services provided by PharmXHealthOne are intended for adults who complete a medical consultation with a licensed provider. Recommendations are based on the provider’s clinical judgment, medical evaluation, and state-specific telehealth regulations. Hormone therapy is not appropriate for all patients, and treatment is only prescribed when medically indicated.

Not a Replacement for Primary Medical Care
Hormone therapy through PharmXHealthOne does not replace regular medical care, physical examinations, or diagnostic evaluations performed by a patient’s primary care provider or specialists. Patients are encouraged to maintain routine medical appointments and screening tests.

Risks & Side Effects
All hormone therapies—including but not limited to testosterone therapy, estrogen therapy, progesterone therapy, thyroid therapy, and adrenal support—carry potential risks and side effects, which may include, but are not limited to:

Changes in mood or emotional state
Changes in libido
Fluid retention
Blood pressure changes
Acne or skin changes
Fertility changes
Red blood cell elevation
Cardiovascular risks (varies by patient condition)

Patients must complete all required labs and follow-up appointments. Failure to comply may result in treatment suspension.

Pregnancy, Breastfeeding, and Safety
Hormone therapy is not approved for pregnant or breastfeeding individuals. Patients must notify their provider immediately if pregnancy occurs or is suspected.

Controlled Substances & Prescribing
Some hormone therapies (e.g., testosterone) are regulated as Schedule III controlled substances under federal law. Prescriptions will follow strict DEA and state guidelines.

State-Specific Restrictions & Clarifications
Florida: Hormone therapy is permitted via telehealth with appropriate labs, patient identification, and follow-up.

California: Telehealth hormone prescribing is permitted but requires clear documentation of medical necessity and patient identity verification.

Texas: Certain hormone replacement medications may require more frequent in-person labs or physical examinations due to state-level telemedicine laws.

New York: Telehealth prescribing of controlled substances requires compliance with NY Office of Professional Discipline rules; testosterone prescribing is permitted only after completing specific telehealth standards.

Alabama: Enhanced telemedicine restrictions may apply; additional documentation or in-state lab verification may be required.

Arkansas: Certain hormones may require an initial in-person examination unless exemptions apply under Act 421 telemedicine statutes.

These rules may evolve. PharmXHealthOne complies with current state and federal prescribing requirements.
Insurance Coverage Disclaimer

Hormone therapy through PharmXHealthOne may or may not be covered by insurance. Patients are responsible for all costs associated with treatment, labs, and follow-ups.

PEPTIDE THERAPY DISCLAIMER (NATIONWIDE TELEHEALTH)
General FDA Regulatory Disclaimer
Most wellness peptides prescribed through PharmXHealthOne—including but not limited to Semaglutide (compounded), Tirzepatide (compounded), BPC-157, CJC-1295/Ipamorelin, GHK-Cu, TB-500, MOTS-C, and others—are considered compounded medications or research peptides.

They may not be approved by the FDA for the specific indications for which they are prescribed, though their individual components may be FDA-approved.

Compounded medications are prepared by licensed U.S. compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug & Cosmetic Act.

Intended Medical Use
Peptide therapies provided by PharmXHealthOne are prescribed only after a medical evaluation determines potential therapeutic benefit. They are intended as part of integrative wellness and functional medicine programs and may not be suitable for all patients.

Risks & Side Effects
Peptide therapies may carry potential risks and side effects, including:

Injection site reactions
Nausea or gastrointestinal changes
Headache, fatigue, or dizziness
Appetite changes
Potential interactions with other medications
Rare allergic reactions

Patients agree to notify PharmXHealthOne immediately if unexpected symptoms occur.

Laboratory Monitoring
Peptide therapy may require baseline and ongoing laboratory testing to ensure safety and effectiveness. Failure to complete required labs may result in treatment suspension.

Not a Substitute for Medical Care
Peptide therapy is not intended to diagnose, treat, cure, or prevent any disease unless indicated by a licensed provider. It should not replace routine medical care, emergency treatment, or primary physician oversight.

State-Specific Restrictions & Clarifications
California: Compounded peptides may only be dispensed from licensed pharmacies compliant with CA Board of Pharmacy regulations; some peptides may require additional clinical justification.

New York: Certain peptides may not be dispensed or may require additional clinical documentation; pharmacies must comply with NY compounding restrictions.

Arkansas: Telemedicine laws may require an initial in-person examination unless statutory exceptions apply.

Texas: Telehealth prescribing of peptides is generally permitted but may require more frequent patient monitoring.

Louisiana: Peptide therapies may require explicit documentation that they are compounded and not FDA-approved for the intended use.

PharmXHealthOne complies with all state-specific prescribing restrictions and documentation requirements.
Athletic / Doping Disclosure

Certain peptides may be banned by WADA, USADA, NCAA, NFL, NBA, MLB, and other athletic governing bodies. Patients are responsible for verifying their compliance obligations.

Pregnancy & Breastfeeding
Peptide therapy is not recommended for individuals who are pregnant, breastfeeding, or planning to become pregnant. Patients must report changes immediately.

Insurance Coverage Disclaimer
Most peptide therapies are not covered by insurance. Patients are responsible for all treatment costs.